Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be46e81b6f0fc43cea2be3a8e7d2dc7af> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be46e81b6f0fc43cea2be3a8e7d2dc7af NCIT_P378 "NCI" @default.
- Be46e81b6f0fc43cea2be3a8e7d2dc7af type Axiom @default.
- Be46e81b6f0fc43cea2be3a8e7d2dc7af annotatedProperty IAO_0000115 @default.
- Be46e81b6f0fc43cea2be3a8e7d2dc7af annotatedSource NCIT_C155294 @default.
- Be46e81b6f0fc43cea2be3a8e7d2dc7af annotatedTarget "A preparation of autologous T-lymphocytes (ATL) that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, encoding a chimeric antigen receptor (CAR) composed of a single chain single-chain variable fragment (scFv) directed against the CD30 antigen (CAR.CD30) and linked, via the spacer human IgG1 immunoglobulin heavy constant region (hinge-CH2CH3 region), to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD30CAR-CD28-CD3zeta-expressing T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies." @default.